If a company builds assets at 11.6% a year, faster than its revenue growth rate of 7.5% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Simcere Pharmaceutical Group's average Total Assets Growth Rate was 6.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 2.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 11.60% per year.
During the past 7 years, Simcere Pharmaceutical Group's highest 3-Year average Total Assets Growth Rate was 23.10%. The lowest was 2.10%. And the median was 16.25%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (HKSE:02096) Total Assets Explanation
Note:
The Net Income data used here is two times the semi-annual (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Simcere Pharmaceutical Group's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Simcere Pharmaceutical Group Total Assets Related Terms
Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Simcere Pharmaceutical Group (HKSE:02096) Business Description
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02096 has been successfully added to your 